89664-09-5

Basic information

• Product Name: Benzenemethanol, a-(4-chlorophenyl)-2-(trifluoromethyl)-
• CAS NO: 89664-09-5
• Molecular Formula: C14H10ClF3O
• Molecular Weight: 286.681
• Mol File: 89664-09-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, a-(4-chlorophenyl)-2-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, a-(4-chlorophenyl)-2-(trifluoromethyl)-(89664-09-5)
• EPA Substance Registry System: Benzenemethanol, a-(4-chlorophenyl)-2-(trifluoromethyl)-(89664-09-5)

Safety Data

• Hazardous Substances Data: 89664-09-5(Hazardous Substances Data)

Upstream product

• 392-83-6 o-trifluoromethylphenyl bromide 
• 104-88-1 4-chlorobenzaldehyde 
• 447-61-0 2-Trifluoromethylbenzaldehyde 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 395-47-1 [2-(trifluoromethyl)phenyl]magnesium bromide 

Downstream Products

• 1028991-38-9 C₁₄H₉Cl₂F₃ 

Relevant articles and documents

CuCl/bipyridine-catalyzed addition reactions of arylboroxines with aldehydes, α,β-unsaturated ketones, and N-tosyl aldimines

CuCl/bipyridine-catalyzed addition reactions of arylboroxines with aldehydes and α,β-unsaturated ketones at elevated temperatures were described. By using the microwave energy, CuCl/bipyridine-catalyzed addition reactions of arylboroxines with aldimines were also realized.

Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands

After the CB1 receptor antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Several series of urea, carbamate, amide, sulfonamide and oxalamide derivatives based on 1-benzhydrylpiperazine scaffold were synthesized and tested for CB1 receptor binding affinity. The SAR studies to optimize the CB1 binding affinity led to the potent urea derivatives. After the additional SAR studies to optimize the substituents of diphenyl rings, the combination of 2-chlorophenyl and 4-chlorophenyl turned out to be the most potent scaffold. The CB2 binding affinity assay as well as functional assay was also conducted on these compounds. Herein we wish to introduce several novel CB1 antagonists with IC50 values less than 100 nM for the CB1 receptor binding.

AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS

Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formuila (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [-CH-0-] group.